Recently, researchers used hIPSCs to examine the possible contributions of SORL1 genetic variation to sporadic AD-related phenotypes and found that human neurons carrying SORL1 variants with an increased AD risk show a reduced response to treatment with brain derived neurotrophic factor (BDNF), at the level of both SORL1 expression and APP processing [48]. This evidence concerns the gene BDNF and Alzheimer disease.